Tag: Statins
ACC: Treat-to-Target LDL-C Strategy Noninferior to High-Intensity Statins
Strategy noninferior for three-year composite of death, myocardial infarction, stroke, or coronary revascularization
Nonacceptance of Statin Recommendation Common, Especially for Women
Nonacceptance of statin therapy associated with longer time to achieve LDL cholesterol of less than 100 mg/dL
Polypill Not Linked to Reduced Cognitive Decline in Seniors
But polypill with or without aspirin is associated with reduced functional decline for those aged 65 years or older with cardiovascular risk factors
Vitamin D No Aid for Statin-Associated Muscle Symptoms
Results consistent regardless of pretreatment 25-hydroxyvitamin D levels
Statin Use Linked to Reduced Risk for Intracerebral Hemorrhage
Risk reduced for lobar and nonlobar intracerebral hemorrhage; greater reductions seen with prolonged use ≥5 years
Clinician Nudge Ups Initiation of Statin Prescribing in Primary Care
Clinician nudge alone or in combination with a patient nudge increases initiation of statin prescribing versus usual care
Cardiovascular Benefits of Statins Outweigh Low Risk for Muscle Symptoms
Only one of 15 muscle symptom-related reports by study participants assigned to statins believed to be due to statins
Guidance Developed for Addressing Use of Nonstatin Therapies
Expert consensus decision pathway developed for patients currently taking statins and needing additional treatment
USPSTF Recommends Statins for Primary Prevention of CVD in Adults
Statin use recommended for adults aged 40 to 75 years with at least one CVD risk factor and estimated 10-year CVD event risk of ≥10 percent
Real-World Data Links Rosuvastatin to Adverse Effects on Kidneys
Greater risks for hematuria, proteinuria seen with higher rosuvastatin dose
